Liraglutide (Lir), a glucagon-like peptide-1 receptor (GLP-1R) agonist, is widely applied to treat T2DM as it can improve hyperglycemia without any risk of hypoglycemia. This evidence concerns the gene GLP1R and Hypoglycemia.